CDEK
← All drugs Report issue

faricimab

Trade name: Vabysmo

mAbapprovedMulti-specific

Approved

Jan 28, 2022

Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection by an ophthalmologist. — Wikipedia

Clinical trial activity

33 trials · 21 clinical orgs · 2 marketing orgs

Phase 1
2
Phase 2
21
Phase 3
14
Phase 4
7

Earliest trial started Dec 1, 2013 (NCT01941082)

Timeline

2010s

  1. Jan 1, 2013

    Roche — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Roche — Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2018

    Roche — Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 28, 2022

    Roche — Earliest FDA Approval

  2. Jan 28, 2022

    Genentech — Marketing Organization

  3. Jan 28, 2022

    Roche — NDA Secondary Org

  4. Jan 28, 2022

    Roche — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJan 28, 2022

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
Yes

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • rg7716
  • rg7716
  • ro6867461

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07187804Phase 4Sep 23, 2025Kim's Eye Hospital, Seoul, South Korea
NCT07249216N/AJul 18, 2025Singapore Eye Research Institute, Singapore National Eye Centre
NCT06908876Phase 2Apr 24, 2025Innovent Biologics (Suzhou) Co. Ltd.
NCT06795048Phase 4Apr 11, 2025Roche
NCT06790784Phase 3Mar 31, 2025Genentech, Jaeb Center for Health Research, National Eye Institute (NEI)
NCT06929507N/AMar 10, 2025University of Alexandroupolis
NCT07144865N/ADec 1, 2024Tianjin Medical University
NCT07093385Phase 2Sep 10, 2024University of Baghdad
NCT06191094Phase 4Jul 12, 2024University of Colorado, Denver
NCT06572553Phase 2/Phase 3 (Phase 3)Mar 1, 2024Zhejiang University
NCT06176352Phase 3Jan 30, 2024Roche
NCT05904028Phase 3Nov 9, 2023Jaeb Center for Health Research, Juvenile Diabetes Research Foundation, National Eye Institute (NEI), National Institutes of Health (NIH)
NCT05941715Phase 4Jul 4, 2023Medical University of Graz
NCT05681884Phase 2May 16, 2023Genentech, Greater Houston Retina Research
NCT06875245Phase 4Mar 31, 2023Teaching Hospital Královské Vinohrady (FNKV)
NCT05610319Phase 3Feb 28, 2023McMaster University, Roche
NCT05610488Phase 4Nov 30, 2022Vista Klinik
NCT05569148Phase 3Oct 17, 2022Roche
NCT06850922Phase 1/Phase 2 (Phase 2)Jun 22, 2022Genentech, Roche
NCT05224102Phase 4Feb 28, 2022Genentech
Showing 20 of 33 trials
Page 1 / 2

Organizations

Research & Development (21)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RocheFor profit181642013
GenentechFor profit4232022
ChugaiFor profit2012021
Jaeb Center for Health ResearchAcademic/Hospital2212023
National Eye Institute (NEI)Government2012023
Greater Houston Retina ResearchAcademic/Hospital1112023
Innovent Biologics (Suzhou) Co. Ltd.For profit1112025
Juvenile Diabetes Research FoundationAcademic/Hospital1012023
Kim's Eye Hospital, Seoul, South KoreaAcademic/Hospital1112025
McMaster UniversityAcademic/Hospital1112023
Medical University of GrazAcademic/Hospital1112023
National Institutes of Health (NIH)Government1012023
Singapore Eye Research InstituteAcademic/Hospital1012025
Singapore National Eye CentreAcademic/Hospital1112025
Teaching Hospital Královské Vinohrady (FNKV)Academic/Hospital1112023
Tianjin Medical UniversityAcademic/Hospital1112024
University of AlexandroupolisAcademic/Hospital1112025
University of BaghdadAcademic/Hospital1112024
University of Colorado, DenverAcademic/Hospital1112024
Vista KlinikAcademic/Hospital1112022
21 organizations
Page 1 / 2

Marketing (3)

OrganizationOrg typeRelationshipDate
GenentechFor profitMKTGJan 28, 2022
RocheFor profitNDA2Jan 28, 2022
RocheFor profitNDAJan 28, 2022